Analyst Ratings For Corcept Therapeutics Incorporated (NASDAQ:CORT)
Today, Corcept Therapeutics Incorporated (NASDAQ:CORT) stock received an upgrade by Cantor Fitzgerald from Neutral to Overweight with a price target of $29.00.
There are 4 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Corcept Therapeutics Incorporated (NASDAQ:CORT) is Buy with a consensus target price of $24.80 per share, a potential 39.09% upside.
Some recent analyst ratings include
- 12/12/2018-Corcept Therapeutics Incorporated (NASDAQ:CORT) gets upgraded to Overweight by Cantor Fitzgerald with a price target of $29.00
- 8/10/2018-Corcept Therapeutics Incorporated (NASDAQ:CORT) had its Hold rating reiterated by Stifel Nicolaus with a $11.00 price target
- 4/13/2018-Corcept Therapeutics Incorporated (NASDAQ:CORT) has coverage initiated with a Buy rating and $32.00 price target
- 12/20/2016-Corcept Therapeutics Incorporated (NASDAQ:CORT) has coverage initiated with a Sell rating and $7.00 price target
- On 11/21/2018 G Leonard Baker Jr, Director, bought 100,000 with an average share price of $12.73 per share and the total transaction amounting to $1,273,000.00.
- On 11/13/2018 G Leonard Baker Jr, Director, bought 200,000 with an average share price of $12.95 per share and the total transaction amounting to $2,590,000.00.
- On 11/9/2018 G Leonard Baker Jr, Director, bought 17,428 with an average share price of $13.00 per share and the total transaction amounting to $226,564.00.
- On 11/7/2018 Robert S Fishman, Insider, sold 8,000 with an average share price of $13.74 per share and the total transaction amounting to $109,920.00.
- On 10/8/2018 Robert S Fishman, Insider, sold 8,000 with an average share price of $13.19 per share and the total transaction amounting to $105,520.00.
- On 9/7/2018 Robert S Fishman, Insider, sold 8,000 with an average share price of $14.57 per share and the total transaction amounting to $116,560.00.
- On 8/20/2018 G Leonard Baker Jr, Director, bought 35,681 with an average share price of $12.92 per share and the total transaction amounting to $460,998.52.
About Corcept Therapeutics Incorporated (NASDAQ:CORT)
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression. It is developing relacorilant that is in a Phase II trial to treat patients with Cushing's syndrome; abraxane in combination with relacorilant, which is in Phase I/II open label trial to treat solid tumors; and selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer. The company is also developing CORT118335 selective cortisol modulator, which is in Phase I/II open label trial for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Recent Trading Activity for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Shares of Corcept Therapeutics Incorporated closed the previous trading session at 17,76 +0,59 3,44 % with 17.73 shares trading hands.